For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and ...

Boston Scientific’s BSX robust MedSurg segment, driven by endoscopy, neuromodulation and urology businesses, is poised for further growth in the upcoming quarters. The long-term prospects of the ...

Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ablation (PFA) system.

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Buying $100 In BSX: If an investor had bought $100 of BSX stock 10 years ago, it would be worth $582.68 today based on a price of $102.96 for BSX at the time of writing.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Boston Scientific (NYSE: BSX) announced today that NICE issued guidance supporting the use of pulsed field ablation (PFA) for treating AFib.

This was the stock's second consecutive day of losses.

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific has become a big deal-maker under chief executive Mike Mahoney. – Topher Cox. For over a decade before the Guidant bidding war, Boston Scientific had been an aggressive deal-maker.